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An orally active ETA/ETB receptor antagonist ameliorates
proteinuria and glomerular lesions in rats with proliferative
nephritis
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An orally active ETA/ETB receptor antagonist ameliorates proteinuria
and glomerular lesions in rats with proliferative nephritis. The prolifer-
ation of mesangial cells and the extracellular matrix expansion constitute
the most outstanding morphological aspects of the majority of progressive
glomerular diseases. In vitro, endothelin-1 (ET-1) is mitogenic for mesan-
gial cells and induces matrix protein synthesis. We studied the possible
participation of ET-1 in the pathogenesis of renal damage in a normoten-
sive model of proliferative nephritis. Coincidentally with maximal protein-
uria and glomerular lesions, an increase was found in the glomerular
mRNA expression of preproET-1 and the ETA receptor (10 and 6 times
compared to controls, respectively), but not of the ET receptor, and in
ET-1 urinary excretion (217 33 vs. 84 4 pg ET-1/24 hr, N = 4 to 5, P <
0.05). By in situ hybridization, an increase in preproET-1 mRNA expres-
sion in glomerular endothelial, epithelial and mesangial cells, and in some
tubular cells was observed. The administration of bosentan, an ETA/ETO
receptor antagonist, had a beneficial effect on the evolution of nephritis,
preventing the appearance of intense proteinuria (76 35 vs. 380 77
mg/24 hr, N = 4 to 5, P < 0.05), the morphological lesions and the renal
function impairment (creatinine clearance 367 46 vs. 268 33
jd/min/100 g, N = 4 to 5). Simultaneously, there was a decrease in ET-1
urinary excretion (88 14 vs. 217 33 pgET-1/24 hr, N = 4,5, P < 0.05)
and in the renal preproET-1 mRNA expression. The mean systolic blood
pressures remained in the normal range in all animals. These data indicate
that ET-1 participates in the pathogenesis of proteinuria and glomerular
injury in a model of proliferative nephritis. The nonpeptidic orally active
ETA/ETB receptor antagonists could be useful in the treatment of some
human nephritis.
The progressive glomerular diseases are characterized by mes-
angial proliferation and extracellular matrix accumulation. Both
aspects have been associated with the onset of proteinuria,
glomeruloscierosis and renal failure [1]. During the last years,
several studies have suggested the participation of a large array of
cytokines, lipid mediators and vasoactive hormones in the patho-
genesis of renal injury [2].
The potential implication of endothelin-1 (ET-i) in the renal
pathology has recently emerged. ET-i is a potent vasoconstrictor
peptide initially isolated from the supernatant of cultured endo-
thelial cells [3j, although it can be synthesized by numerous cells,
including various renal cell types [4]. Besides its effects on renal
and systemic hemodynamics, ET-1 elicits many other different
biological actions [4]. In vitro, ET-1 promotes cell proliferation
and synthesis of extracellular matrix proteins and induces the
expression of protooncogenes and early genes in different cell
types [4, 51, suggesting that an alteration of ET could contribute to
the onset and progression of renal failure. In different models of
renal injury, such as renal mass ablation, puromycin nephrosis,
diabetic rats and lupus nephritis, an up-regulation of renal ET-1
gene expression, correlating with the progression of the disease,
has been found [6—9]. Further implication of ET-1 in those
settings has been supported by the beneficial effect of a specific
ETA receptor antagonist on renal disease progression [10, 11].
Since systemic hypertension is often seen in animals with these
models of renal injury, the beneficial effects observed with the
ETA receptor antagonists could be due to their antihypertensive
actions.
In this work we have studied the potential participation of ET-1
in the pathogenesis of renal damage in a normotensive model of
immune complex proliferative nephritis. This model shows a
similar histological pattern to that of lupus and mesangiocapillary
nephritis in humans [12, 13]. It is characterized by intense
mesangial cell proliferation, matrix expansion and glomerular and
interstitial infiltration of mononuclear cells [12, 13]. The absence
of hypertension in those animals [141 allows us to separate the
EU-i effects on systemic hemodynamics from those exerted in an
autocrine or paracrine manner on renal cells. Therefore, we
investigated the steady-state mRNA expression of ET-i and its
receptors, as well as the mature protein ET-1 level in the kidneys
of rats with proliferative nephritis. We also tested whether or not
an orally-active dual ETA/ETB receptor antagonist protected
riephritic rats against functional and structural renal damage.
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Immune complex nephritis
All studies were performed in female Wistar rats initially
weighing between 220 and 250 g. During the entire study animals
were given a standard diet and had free access to water.
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Immune complex nephritis was induced according to a previ-
ously described protocol [15]. The animals received an initial
subcutaneous injection of 5 mg ovalbumin (Sigma Chemical
Company, St. Louis, MO, USA) diluted in 250 rl isotonic saline
(0.9% NaC1) emulsified with 250 l complete Freund's adjuvant
(Difco Laboratories, Detroit, MI, USA). After three weeks, the
animals received a subcutaneous booster injection consisting in
the same dose of ovalbumin in incomplete Freund's adjuvant
(Difco Laboratories). One week later, daily intraperitoneal ad-
ministration of 10 mg ovalbumin was started.
From the third week of daily ovalbumin injection, proteinuria
was measured by the sulfosalicylic acid method to monitor the
course of kidney disease. By week 4, a group of rats was killed in
the early stage of the disease (mild nephritis; proteinuria < 15
mg/24 hr and mesangial deposits [131). By around week 5, when
proteinuria reached 30 to 60 mg!24 hr, the animals were randomly
distributed into two groups. One group was treated with the
nonpeptidic ETA/ETB receptor antagonist bosentan (Ro 47-0203;
4-tert-butyl-N- [6-(2-hydroxy-ethoxy]-5-(2-methoxy-phenoxy)-2,2'-
bipyrimidin-4-ylJ-benzene-sulfonamide, Hoffmann-La Roche Ltd,
Basel, Switzerland) during 21 days. For its administration, a daily
bosentan suspension (100 mg/kg) in a dissolution of 5% arabic
rubber was administered by gastric gavage with a cannula. The other
group received a dissolution of 5% arabic rubber for 21 days and
served as non-treated group (severe nephritis or late nephritis). A
control group of healthy animals was used for the duration of the
study.
At the time of sacrifice, diseased animals and healthy controls
were anesthesized with 5 mg/I 00 mg sodium pentobarbital. Blood
was drawn, kidneys were removed to obtain a sample for histo-
logical studies, in situ hybridization and immunohistochemistry,
and cortex was dedicated to isolation of glomeruli.
Biochemistry and processing of renal tissue
At the end of the period of study, serum levels of creatinine,
albumin, triglycerides and cholesterol were determined by stan-
dard methods using an autoanalyzer (Technicon SMAC System).
Creatinine clearance was calculated from an urine sample taken
24 hours before the animal sacrifice.
For light microscopy analysis, in situ hybridization and immu-
nohistochemistry, renal tissue was fixed in 10% buffered formalin
and embedded in paraffin. All these studies were performed
without the observer knowing to which group animals belonged
(double blind study).
Bloodpressure measurement
Systolic arterial blood pressure was measured in conscious,
restrained rats by tail-cuff sphyngomanometer (NARCO Biosys-
tems, CO, USA). The blood pressure value for each rat was
calculated as the average of four separate measurements at each
session.
Renal histopathological studies
For light microscopy, sections (4 sm thick) were prepared and
stained with hematoxylin and eosin, and Masson trichrome. For
each animal, around 30 glomeruli were examined and the histo-
pathology was graded from 0 to 4+ by a semiquantitative score
according to the following criteria: 0, normal; 1+, mild mesangial
cell proliferation and matrix expansion; 2+, more extensive
mesangial proliferation and matrix expansion; 3+, diffuse glomer-
ular proliferation with basement membrane thickening; and 4+,
all the above changes associated with wire ioop lesions, glomeru-
lar sclerosis and interstitial fibrosis.
Isolation of glomeruli
Glomeruli were isolated according to a previously published
sieving technique [16], washed and used for mRNA expression
experiments.
Endothelin extraction and assessment in plasma and urine
At sacrifice, a sample of blood was collected by aortic puncture
into cold tubes containing EDTA (2 mg/ml) and aprotinin (500
U/ml), two protease inhibitors. As soon as possible, the samples
were centrifuged at 2500 rpm for 15 minutes, the plasma collected
and stored at —70°C until the ET was extracted. Urine was
collected during the 24 hours prior to the sacrifice of animals.
Four milliliter aliquots were separated and frozen at —70°C until
use.
ET was extracted from a 1 ml aliquot of plasma and 4 ml
aliquots of urine using a Sep-Pak C1 disposable column (Waters,
Milford, MA, USA), as previously described [17]. In both cases,
the eluted fractions were evaporated in a N2 atmosphere and the
residues stored at —20°C until radioimmunoassay (RIA) was
performed.
ET-1 was measured in each sample by a commercial RIA
(Peninsula Laboartories, Inc., Belmont, CA, USA). The samples
were resuspended in RIA buffer immediately before the assay,
those of plasma in 150 tl and those of urine in 400 tl. The ET-1
antibody used in the RIA had a 7% cross-reaction with ET-2 and
ET-3 and 17% with the Big-ET (human). The cross-reactivity with
nonrelated peptides (ANP, BNP, Ang II, vasopressin and VIP)
was 0%.
Reverse transcription (RT)
From each animal, total RNA was obtained from isolated
glomeruli by the acid-guanidinium-phenol-chioroform method
[181, precipitated with isopropanol and the pellet washed with
70% cold ethanol. The resultant pellet was dissolved in diethylpy-
rocarbonate-treated H20 and the concentrations of total RNA
were then calculated by spectrophotometric measurements at 260
nm.
To obtain eDNA for the polymerase chain reaction (PCR), 1 jg
of RNA from each animal was transcribed in a final volume of 20
jd which contained 5 m'vi MgCl2, RT buffer (10 mi Tris-HC1, 50
mM KCI and 0.1% Triton X-100), 1 mvi deoxynucleotide mixture
(dNTP), 20 units RNasink, 15 U of reverse transcriptase of the
avian Moloney virus (AMV) and 50 ng random primer. The
reaction mixture was incubated at 42°C for 45 minutes. At the end
of the incubation, the samples were heated at 95°C to eliminate
the transcriptase activity and to denaturalize the RNA-cDNA
hybrides. Four microliters of eDNA templates were used for each
PCR reaction of preproET-1, ETA and ET1 receptors and 2 uI for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
PR and analysis of its products
PCR was performed with rat preproET-1, ETA and ETB
receptors and GAPDH specific oligonucleotides primers (Ramon
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Cornet, Madrid, Spain). PreproET-1 sense primer 5'-TGATCT-
TCTCTCTGCTGTTTGTGG-3' corresponded to nucleotides 17
to 40, and the antisense primer 5'-TCTTITACGCCTTTCTG-
CATGGTAC-3' corresponded to nucleotides 401 to 425 of the
published sequence [19]. ETA receptor sense primer 5'-
GAAGTCGTCCGTGGGCATCA-3' corresponded to nucleo-
tides 495 to 514, and the antisense primer 5'-CTGTGCT-
GCTCGCCCTTGTA-3' corresponded to nucleotides 691 to 710
of the published sequence [20]. ET8 receptor sense primer
5'-TTACAAGACAGCCAAAGACT-3' corresponded to nucleo-
tides 801 to 820, and the antisense primer 5'-ACGATGAGGA-
CAATGAGA1T-3' corresponded to nucleotides 1345-1365 of
the published sequence [21]. We performed RT-PCR of GAPDH
as an internal standard. GAPDH sense primer 5'-AATGCATC-
CTGCACCACCAA-3' corresponded to nucleotides 439 to 458,
and the antisense primer 5'-GTAGCCATA'FFCATFGTCATA-3'
corresponded to nucleotides 934 to 954 of the published sequence
[22]. The cDNA amplification products were predicted to be 409,
216, 565 and 516 base pairs (bp) in length. Ten picomoles of sense
and antisense primers, 0.5 jxCi dCTP-a32P (>3000 Ci/rnmol,
Amersham International, Buckinghamshire, UK) and 1.5 U Taq
DNA polymerase were used per reaction. The reaction mixture
(20 pl) was overlaid with mineral oil. The tubes were placed on a
Thermal CyclerR (Perkin Elmer Cetus, Emeryville, CA, USA),
which was programmed as follows: incubation at 92°C for 30
seconds; and then, 30 cycles of the following sequential steps: (a)
preproET-1, 92°C for 30 seconds, 59°C for one minute, 73°C for
one minute; (b) ETA receptor, 92°C for one minute, 60°C for one
minute, 72°C for one minute; (c) ETB receptor, 92°C for one
minute, 57°C for one minute, 72°C for one minute; (d) GAPDH:
92°C for 30 seconds, 54°C for one minute, 73°C for one minute;
finally, incubation was done at 72°C for seven minutes. The
optimum number of amplification cycles used for quantitative
RT-PCR was chosen based on pilot experiments that established
the exponential range of the reaction. In all experiments, the
presence of possible contaminants was checked by control reac-
tions in which amplification was carried Out in the absence of
reverse transcriptase. PCR amplified products were saved and
kept at —20°C until analysis.
The PCR products were size-fractionated with 1.5% agarose gel
electrophoresis and the DNA bands visualized with ethidium
bromide staining. PCR products were blotted to Gene Screen
(DuPont New England Nuclear, Boston, MA, USA) in 0.4 N
NaOH. After the transfer, the membrane was washed in excess
2 X SSC for one to two minutes and the blotted DNA was fixed
to the membrane by ultraviolet-irradiating for two to three
minutes. The dried membranes were exposed to X-Omat AR
films and intensifying screens at —70°C. The optical density of
mRNA for PCR products of preproET-1, ETA and ET receptor
and GAPDH on the autoradiograph was quantified using scan-
ning densitometry (Molecular Dynamics, Sunnyvale, CA, USA).
In situ hybridization
Digoxigenin-laheled single-strand RNA probes of preproET-1
were prepared using a nonradioactive RNA labeling Kit (Boehr-
inger Mannheim, Mannheim, Germany) according to the manu-
facturer's instructions. Sense and antisense preproET-1 ribo-
probes were synthesized from a linearized plasmid PMAM
neoblue containing a fragment of the rat preproET-1 as run-off
transcripts with T3 and T7 RNA polymerases in the presence of
digoxigenin-1 1-UTP.
Paraffin-embedded renal tissue was cut at 4 jim and floated
onto APES (Sigma) coated slides. The hybridization was per-
formed with modifications of a previously described protocol [23].
The tissue sections were heated at 65°C overnight and then fixed
with 1.5% paraformaldehyde-1.5% glutaraldehyde. After dewax-
ing, the tissues were incubated in 5 mvt levamisole. Deproteiniza-
tion was carried out in 0.2 N HCI and followed by digestion with
proteinase K to better expose the RNA target. After digestion, all
sections were post-fixed as above and dehydrated and air dried at
room temperature. The slides were hybridized with 10 ng/jxl
denatured digoxigenin-11-UTP-labeled riboprobes in hybridiza-
tion buffer [2 X SSC, 1 X Denhardt's solution, 0.1 M sodium
phosphate (pH 6.5), 10% dextran sulfate (in formamide)]. Sealed
cover slips were placed over the tissue sections and the hybridiza-
tion was allowed to occur overnight at 42°C in a moisturized
chamber. The cover slips were removed and the slices were
washed in 2 x SSC for one hour at room temperature. This was
followed by incubation in 1 x SSC for one hour at room
temperature, 0.5 X SSC for 45 minutes at 37°C and, finally, 0.2 X
SSC for 30 minutes at 37°C. The sections were incubated with an
anti-digoxigenin antibody conjugated with alkaline phosphatase
(Boehringer Mannheim) for 30 minutes at 37°C. Colorimetric
detection of RNA-RNA hybrids was performed with nitroblue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphate (X-
phosphate) in the dark for three to eight hours. The color reaction
was stopped with 10 mr'i Tris-HCI, 1 mi EDTA (pH 8) and then
cover slips applied with 60% glycerol before microscopic exami-
nation. The negative controls included: (1) hybridization with the
sense probe, (2) RNAse treatment before hybridization, and (3)
omission of the RNA probe.
500
400
300
E 200
100
0
4 5 6 7 8 9
Time, weeks
Fig. 1. l]rinaiy protein excretion in rats with non-treated nephritis (0) and
rats treated with bosentan (100 mg/kg/day orally; •). Data represent
mean SCM, N = 4 to 5, P < 0.05 respect to non-treated animals at the
corresponding time.
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Table 1. Serum and renal parameters in control, nephritic and bosentan-treated rats
Proteinuria
mg/24 hr
Cholesterol Triglycerides Albumin
g/dl
Creatinine clearance
1.d/min/100 gmg/dl
Control 3 1 73 6 30 5 3.8 0.1 379 55
Mild nephritis 8 2" 62 12h 38 8 3.5 0.1 338 23
Severe nephritis
Bosentan-treated nephritis
380 77°
76 35"
255 63°
32 4"
344 148
55 13
2.1 0.5
3.3 0.7
268 33
367 46
The values show the mean SCM of the individual values of animals from each group.
P < 0.05 with respect to healthy control rats
b P < 0.05 with respect to rats with severe nephritis
Fig. 2. Histological analysis showing pathological changes in glomeruli of healthy control rats (A), non-treated nephritic rats (B), mild nephntis rats (C) and
bosentan-treated rats (D). Microphotographs showing Masson's trichrome staining of the glomeruli (magnification x 400).
Tissue localization of endothelin-like immunoreaclivity
Paraffin-embedded renal tissue was cut at 4 m and mounted
on poly-L-lysine-coated slides. Immunoperoxidase staining was
performed by the avidin-biotin-peroxidase complex method [24].
The slides were incubated overnight at 65°C and deparaffinized
with graded concentrations of xylene and ethanol. The slides were
quenched in methanol containing 3% H202 at 25°C for 30
minutes. The sections were washed and incubated in trypsin (0.1%
trypsin in 0.1% CaCl2 wt/vol) to activate antigen ic sites. They were
subsequently incubated with 5% normal swine serum for 30
minutes at room temperature to reduce nonspecific background
staining and then incubated overnight at 4°C with rabbit poiy-
clonal anti-ET-1 antibody (Peninsula Laboratories) diluted 1:1000
in PBS containing 5% normal swine serum. The control slides
were treated with diluted normal rabbit serum. After being
washed in PBS, the sections were incubated with biotinylated
swine antirabbit IgG (Dako A/S, Glostrup, Denmark) at a dilution
of 1:200, and after further washing, incubated with avidin-biotin-
peroxidase complex (Dako AJS) diluted 1:100 in PBS for 30
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Fig. 3. Urinary endothelin (ET-1) excretion in control and nephritic (non-
treated and bosentan-treated, 100 mg/kg/day) rats. Mean SEM, N = 4 to 5.
< 0.05 respect to control animals, P < 0.05 respect to the animals
with severe nephritis.
Fig. 4. Gene expression of preproET-1 and ETA and FT8 receptors in
glomeruli of control and nephritic (non-treated and bosentan-treated, 100
mg/kg/day) rats. A representative animal of each group is shown. Arrows
indicate the expected size for each PCR product.
minutes. The sites of peroxidase activity were visualized with
0.05% 3,3'-diaminobenzidine (Dako A/S) in 0.01% H202 for 10
minutes, The sections were counterstained with Mayer's hema-
toxylin (Sigma).
Around 15 glomeruli from each animal were examined and the
immunostaining was graded from 0 to 4+ by a semiquantitative
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Fig. 5. Densitomety analysis of mRN.4 glornerular expression of preproET- 1
(A) and ETA (B) and ET8 (C) receptors in control and nephritic (non-treated
and bosentan-treated, 100 mg/kg/day) rats. Results arc expressed as the
fold-increase of healthy control rats. Data are mean SEM of 4 to S
animals in each group, *p < 0.05 versus control rats.
score according to the following criteria: 0, no staining; 1+,
minimal staining; 2+, mild staining; 3+, moderate staining; 4+,
marked staining.
Statistical analysis
Results are expressed as mean SEM. Significance at the 95%
level was established using ANOVA and Student's t-test. The
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Serum and urine ET-1 levels
Fig. 6. Absence of labeling in renal rat (issue hybridized with a sense
rihoprohe for preproET-1 (magnification X J0O).
Kolmogorov-Smirnov test was used to assess the normal distribu-
tion of data. The Mann-Whitney U test for nonparametric values
was used for histological data.
Results
Effect of bosentan on proteinuria, renal Junction and
morphological lesions
In this model of proliferative glomerulonephritis, immune
deposits are initially restricted to the mesangium, and urinary
protein excretion is within normal limits (< 15 mg124 hr; mild
nephritis) [12, 13, 251. Thereafter, immune deposits extend to the
glomerular capillary wall and proteinuria rises above normal. At
this stage randomly assigned to received either bosentan 100
mg/kg/day (bosentan-treated group) or vehicle (non-treated
group) for 21 days. Proteinuria at the start of therapy was 43 9
mg/24 hr and 53 14 mg/24 hr, respectively (P = NS). In
non-treated rats, proteinuria increased over three weeks of study,
progressing to a full-blown nephrotic syndrome (Fig. 1). The
administration of bosentan avoided the development of intense
proteinuria (at the end of the study, 76 35 vs. 380 77 mg/24
hr; N = 4 to 5, P < 0.05; controls 3 1 mg/24 hr). Concomitantly,
bosentan-treated animals showed an improvement in the renal
function (measured as creatinine clearance) with respect to
nephritic rats (367 46 vs. 268 33 pi/min/100 g, N = 4 to 5;
controls 379 55 d/min/100 g) and in serum lipids (cholesterol
and triglycerides) and albumin (Table 1).
Mean systolic blood pressure in all rats was in the normotensive
range throughout the three weeks of study, and the administration
of hosentan did not significantly modify the blood pressure
(control rats 107 ii; ncphritic rats 115 11; bosentan-treated
rats 104 8 mm Hg, N = 4 to 5, P = NS in all group).
Studies from our group have detailed the morphological aspects
of glomerular lesions in this model [14, 15]. At the end of the
three weeks of study, non-treated rats showed glomerular hyper-
cellularity, matrix expansion, and mononuclear cell infiltration in
the glomeruli and in the interstitium (Figs. 2 and 9). By contrast,
the bosentan-treated animals showed a significant diminution in
the glomerular structural damage, with discrete evidence of
mesangial hypercellularity and matrix expansion (Figs. 2 and 9).
Initially, we determined whether in this experimental model
there existed an alteration in the ET synthesis which could cause
an increase in the plasma and/or urinary levels of ET. Blood and
urine samples were taken from the treated and non-treated
nephritic animals and ET was extracted for quantification. The
ET-1 plasma levels were similar in all groups studied (control
5.4 1.9; mild nephritis 4.5 0.7; severe nephritis 3.9 0.1,
bosentan-treated nephritis 4.7 1.1 pg ET-1/ml plasma, N =4 to
5, P = NS for all groups).
In spite of the absence of significant differences between plasma
ET levels, an increase in the ET urinary excretion was already
seen in animals with mild nephritis, with a further augmentation
in those with severe nephritis (Fig. 3). Surprisingly, bosentan
significantly reduced the urinary ET-1 excretion to values similar
to those of control animals (Fig. 3).
Renal preproET-1 and ET receptors mRNA expression
The steady state mRNA levels for preproET-1 and its receptors
in the glomeruli of control and nephritic rats (treated and
non-treated) were determined by RT-PCR. The expected size of
each PCR product was apparent: preproET-1 409 bp, ETA
receptor 216 bp, ET8 receptor 565 bp, and GAPDH 516 bp. The
amplification product of GAPDH served as internal standard for
RT-PCR reaction. Figure 4 shows an autoradiograph of all PCR
products of glomeruli from a representative animal from each
group.
The densitometric analysis of preproET-1 and ETA receptor
mRNA signals shows an increase in the expression according to
the progression of the disease, although no change in ETB
receptor mRNA levels was observed (Fig. 5). With respect to
healthy control rats, the preproET-1 and ETA receptor expression
was already increased in early phases of nephritis (6- and 3-fold,
respectively) with a further augmentation in rats with severe
nephritis (10- and 6-fold, respectively).
Animals receiving bosentan had a certain decrease in the
preproET-1 expression, though not significant, in relation to rats
with severe nephritis (Fig. 5). Bosentan reduced the ETA mRNA
expression in bosentan-treated rats although it had no effect on
ET mRNA expression (Fig. 5).
In situ hybridization for preproET-1 mRNA
The cellular distribution of preproET-i mRNA in the kidneys
of animals from different groups was investigated by in situ
hybridization using digoxigenin-laheled riboprobes. In control
experiments, hybridization with the sense riboprobe (Fig. 6),
RNAse treatment before hybridization or the omission of the
RNA probe did not label any renal structures. By contrast,
hybridization of kidney sections from normal rats with the anti-
sense riboprobe yielded a patchy labeling in glomerular capillary
walls, mesangial cells and parietal and visceral glomerular epithe-
hal cells, as well as in the luminal pole of some proximal tubular
cells and in some vessels (Fig. 7A). A nearly identical labeling
pattern of the renal structures was observed in rats with nephritis,
although the intensity was stronger (Fig. 7B). The administration
of bosentan decreased the mRNA expression of preproET-1 in all
renal structures, principally in proximal tubules (Fig. 7C). Previ-
ous studies in our laboratory showed that nephritic rats have an
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Fig. 7. Cellular distribution of preproET-1 mRNA in control rats (A), rats with severe nephritis (B) and rats with nephritis treated with bosentan (C). (D)
Mononuclear cells around a vessel showing an intense preproET-1 mRNA expression. Note that no staining was seen in the endothelial surface of this
medium-sized vessel. A digoxigenin-labeled antisense riboprobe specific for preproET-1 was hybridized under high-stringency conditions with kidney
sections (magnification X 100).
important interstitial infiltrate of monocytes/macrophages and T
lymphocytes [14, 15]. By in situ hybridization the mononuclear
cells intensively took the labeled preproET-1 probe (Fig. 7D).
Tissue localization of endothelin immunoreactivily
Endothelin immunoreactivity was identified in the renal cortex
and medulla of control rats. No immunoperoxidase staining was
observed in the samples from control and nephritic rats (treated
and non-treated) when a non-immune serum was used (not
shown). At the glomeruli, immunostaining was localized in a
patchy distribution in endothelial and epithelial cells and mesan-
gial regions (Fig. 8A, and Fig. 9). Very marked immunostaining
was seen in the endothelium of peritubular capillaries. Focal
immunostaining was also noted in the brush border of some
proximal tubules (not shown). In the animals with severe nephri-
tis, the distribution of the immunostaining was similar, but with a
greater intensity (Fig. 8B and Fig. 9). The administration of
bosentan to nephritic rats diminished the immunostaining in an
appreciable manner, hut it remained above control rats (Fig. 8C
and Fig. 9).
Discussion
In this work we provide evidence that ET- 1 is implicated in the
pathogenesis of glomerular injury in a normotensive model of
immune complex proliferative nephritis. We demonstrate that rats
with nephritis have an increase in the renal gene expression of
preproET-1 and its ETA receptor, in the mature ET-1 peptide as
well as in its urinary excretion, coinciding with the major glomer-
ular lesions. This study also shows that the administration of an
orally active ETA/ETB receptor antagonist decreased proteinuria
and attenuated the morphological lesions in this model.
Our results clearly suggest that the ET-1 generated in the
kidney may participate in the generation of glomerular damage in
a proliferative model of immune complex nephritis. In fact, a good
correlation between urinary ET-1 excretion and the renal expres-
sion of preproET-1 mRNA and its protein was noted, while no
appreciable changes existed in the blood levels of the peptide.
These results are in agreement with that previously observed in
the renal ablation model [17], and indicate that urinary ET-1 is
probably originated in the kidney. Indeed, less than 0.3% of ET
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was recovered in the urine after the infusion of radiolabeled ET,
indicating that ET formed in the systemic circulation is not likely
to be excreted in the urine in a significant manner [17]. Interest-
ingly, the ET-1 overexpression was already seen in the early phase
of nephritis, suggesting its direct implication in the glomerular
lesions in this model. By in situ hybridization, in control animals
the preproET-1 gene expression was observed in a patchy distri-
bution in the glomerular capillary walls, glomerular mesangial and
epithelial cells, in the luminal pole of some proximal tubules and
in some vessels. In rats with severe nephritis, there was an
important increase in the gene expression in all these areas, but
with the same localization. Previous in situ hybridization studies
had localized ET-1 mRNA in the medulla with a distribution
along the vasa recta, hut not in glomeruli. However, the autora-
diography technique employed by these authors [26] is several-
fold less sensitive than the digoxigenin labeled probe used in the
present work [27]. Our results are in agreement with in vitro
studies in which mesangial, glomerular epithelial and endothelial
cells can express the ET-1 gene and synthesize the protein under
appropriate stimuli [28—331. Interestingly, an intense preproET-1
expression was seen in the cells infiltrating the interstitium of rats
with severe ncphritis. Although double immunostaining studies
were not performed in the present study, it has been demon-
strated that resting or stimulated cultured human macrophages
produce and release abundant mature ET-1 [34]. Therefore, we
cannot discard that these cells may also contribute to the kidney
content of ET-1 and participate in tissue injury.
The mechanisms of ET-1 overexpression in the kidney of
animals with immune injury are unclear. In several models of
glomerulonephritis, including the model used in this work, an
increase in the glomerular expression and synthesis of growth
factors and cytokines, such as transforming growth factor 13
(TGF13) and tumor necrosis factor (TNF), was observed
coinciding with the major injury [9, 14, 15]. In vitro, glomerular
cells can synthesize ET-1 in response to numerous proinflamma-
tory stimuli, including TGFJ3 and TNFa, two cytokines that arc
implicated in the pathogenesis of kidney diseases [2, 16, 28—33,
35]. It is tempting to speculate that during renal injury, both
infiltrating inflammatory and resident cells may release those
mediators, stimulating mesangial cells to increase ET-1 synthesis
that could further induce cell proliferation and matrix protein
production [4, 5, 35]. ET-1, in turn, also increases the expression
and synthesis of several cytokines, including PDGF and TGFI3,
that could mediate the ET-1 effects on renal cells [4, 36].
Recently it has been demonstrated that mRNA of both sub-
types of ET receptors can be localized in the glomerulus by
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Fig. 9. Histological score by light microscopy (A) and glomerular ET-1
immunostaining score (B) of control (s), non-treated •) and bosentan-
treated (100 mg/kg/day; ) rats. Mean SCM of 4 to 5 animals in each
group. < 0.05 versus control rats; #P < 0.05 versus rats with severe
nephritis.
RT-PCR [37]. ETA and ET receptors have different structures,
function and distribution [38]. However, the regulation and
expression of both receptors in renal tissue during injury are
hardly known. In this work, we have observed an increase in the
ETA receptor mRNA expression during the progression of the
disease, without changes in the mRNA levels of ETB receptor.
Several authors have described that ET-1 produced by cells in
culture can down-regulate ET receptors by an autocrine mecha-
nism [39, 40]. However, an up-regulation of ET receptors associ-
ated with increased preproET-1 mRNA levels have been observed
in various diseases [9, 41, 42]. Since ETA has been associated with
cell proliferation and matrix protein synthesis [4, 35], the increase
in the ETA receptor mRNA expression in the kidney from animals
with severe nephritis, in the presence of unaltered ET receptor
levels, would further enhance these effects of ET-1 in renal cells.
To demonstrate in a more direct manner the participation of
ET-1 in this nephritis, a group of animals received hosentan, a
new orally-active ETA and ETB receptor antagonist [43]. Though
bosentan is a competitive antagonist of both receptors, functional
and binding studies have shown that it is more specific for ETA
than for ET [43]. The administration of bosentan to animals with
established nephritis (proteinuria 30 to 60 mg/24 hr) during 21
days diminished the renal permeability to proteins, limited gb-
merular injury and prevented renal function deterioration. Recent
studies have shown that an ETA receptor antagonist protected
against injury in a remnant kidney model and in mice with lupus
nephritis [10, 11], tvo situations commonly associated with ele-
vated systemic blood pressure. Therefore, the beneficial effect of
the ETA receptor antagonists could be due to the antihypertensive
actions of those compounds. Since blood pressure remained
normal in all animals with immune nephritis during the period of
study [14], and bosentan did not modify it in a significant manner,
our data suggest that the improvement observed with this therapy
may be due to the blockade of direct ET-1 effects on the kidney.
However, we cannot discard that bosentan ameliorated intraglo-
merular hypertension in the immune nephritis, though, to our
knowledge, that has not been determined in this model.
Since the ETA receptor mediates constriction, cell proliferation
and matrix protein production by cultured mesangial cells [4, 5],
one can speculate that blocking ETA receptor would limit the
biological consequences of ET-1. The role of the ET8 receptor
blockade in the improvement observed by bosentan in our model
is uncertain. The ETB receptor mRNA is also abundant in the rat
kidney [4] and its expression was found increased in the remnant
kidney [44]. In this model of progressive renal disease, a similar
amelioration in proteinuria and renal function was noted with
both ETA and ETA/ETB receptor antagonists. Therefore, the
authors suggested that ETB receptor was only marginally involved
in ET-related renal disease progression [44].
Rats treated with bosentan had also a diminution in the ET-1
urinary excretion and in the preproET-1 mRNA expression, as
could be verified by RT-PCR and in situ hybridization. The
reasons of this phenomenon are not clear. As ET-1 induces its
own expression and synthesis in several cells through the ET
receptor [4, 45], one can speculate that bosentan, by blocking the
ET-1 binding to both ETA and ETB receptors, could modify the
synthesis of a large array of inflammatory mediators and that of
ET-1 itself. This could theoretically be an additional advantage of
dual (ETA and ETB) versus specific ETA receptor antagonists, but
deserves further study.
On the whole, this work presents strong evidence that ET-1 is
involved in the pathogenesis of glomerular damage in a normo-
tensive model of immune injury. The beneficial effect of bosentan,
a nonpeptidic oral ETA/ETa receptor antagonist, suggests that
those kinds of compounds could eventually he used in human
nephritis.
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